GLPwatch

Chinese, Overweight or Obesity, Real-World Registry Study

NCT07525037 · Not yet recruiting

Last updated 2026-05-28

This study is examining how overweight and obese adults in China with type 2 diabetes are currently being treated in real-world settings.

Status Not yet recruiting Approved but enrollment has not started.
Type Observational
Participants 10,000 people Planned (estimated).
Who can join all sexes
Timeline Started 2026-05 · est. completion 2027-12
Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07525037 ↗

Description as written by the study sponsor.

This study will enroll 10,000 patients with obesity, with the participation of approximately 50 medical institutions nationwide. At baseline, demographic data, physical examinations, multiple laboratory tests (including complete blood count, urinalysis, liver/renal function, electrolytes, thyroid function panel \[3 items\], urine albumin/creatinine ratio, fasting glucose, fasting C-peptide, fasting insulin, HbA1c, blood lipids, etc.) and hepatic elasticity ultrasound will be performed. Patients will receive weight-loss therapy in routine clinical practice. Data on clinic visits, adverse events, and changes in therapeutic regimens will be centrally collected by investigators or their authorized representatives at Week 26 and Week 52.

Main thing measuredThe treatment model for overweight and obese individuals in China at present.
SponsorChinese PLA General Hospital
Conditions studiedObesity Type 2 Diabetes Mellitus
GLP-1 drugs

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07525037 ↗